
    
      This is a study to determine the safety and efficacy of brentuximab vedotin in subjects with
      classic Hodgkin lymphoma (cHL) and systemic anaplastic large cell lymphoma (sALCL) or other
      CD30-expressing peripheral T cell lymphoma (PTCL) who experienced complete response (CR) or
      partial response (PR) with a brentuximab vedotin-containing regimen and subsequently
      experienced disease progression or relapse.
    
  